Ground-Breaking Test Assesses Expansion and Persistence of CAR-T Therapy in Cancer Patients

Research has shown that the persistence and expansion of CAR-T therapy are important indicators of how long the therapy can remain effective in the patient. Now, a ground-breaking test provides clinicians with an accurate and comprehensive assessment of the CAR-T cell population in the patient's body and offers insights to therapy effectiveness.

Eurofins Viracor LLC (Lenexa, KS, USA) has launched the ExPeCT CAR-T multiplexed quantitative real-time PCR (qPCR) assay that acts as a powerful diagnostic tool to monitor and optimize CAR-T therapy involving patients with pre-B cell acute lymphoblastic leukemia and B cell lymphomas. The test, based on a method developed by Eurofins Viracor, is designed to help clinicians better understand how CAR-T therapy is performing for their patients. The test marks an important step forward in the evaluation and management of CAR-T therapy in cancer patients by helping clinicians to make more informed decisions about the best course of treatment for their patients.

Related Links:
Eurofins Viracor LLC